secwatch.observer — SEC 8-K summary
======================================

Issuer:     Alzamend Neuro, Inc. (ALZN)
CIK:        0001677077
Form:       8-K
Filed at:   2024-05-22T23:59:59+00:00
Accession:  0001214659-24-009785
Event type: regulatory
Sentiment:  neutral
Materiality: 0.70
Item codes: 7.01, 3.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Alzamend Neuro gets Nasdaq extension to meet $2.5M equity rule by Sept 23, 2024
-------------------------------------------------------------------------------

- Nasdaq Hearings Panel granted continued listing on Capital Market, subject to compliance with Listing Rule 5550(b)(1).
- Company must demonstrate stockholder equity of at least $2.5 million on or before September 23, 2024.
- Appeal hearing held May 9, 2024; panel decision received May 21, 2024.
- CEO Stephan Jackman stated company is implementing its compliance plan.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1677077/000121465924009785/0001214659-24-009785-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1677077/000121465924009785/p5212408k.htm
  HTML page:      https://secwatch.observer/filing/0001214659-24-009785

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer